Please login to the form below

Not currently logged in
Email:
Password:

SMA Europe

This page shows the latest SMA Europe news and features for those working in and with pharma, biotech and healthcare.

Novartis faces criticism over Zolgensma ‘health lottery’

Novartis faces criticism over Zolgensma ‘health lottery’

SMA Europe deems access programme 'inappropriate'. Novartis has responded to criticism over its managed access programme for spinal muscular atrophy (SMA) gene therapy Zolgensma, with patient groups accusing the company of ... For SMA Europe, the fact

Latest news

  • CHMP backs two rare disease therapies at April meeting CHMP backs two rare disease therapies at April meeting

    Biogen closed in on EU approval of its spinal muscular atrophy (SMA) treatment Spinraza (nusinersen) in Europe, having already picked up a US approval for the highly-priced drug as 2016 ... Spinraza is the first drug for the rare and often fatal genetic

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Guide
How to embrace behavioural science principles in healthcare MR...
Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...